Last reviewed 2026-06-02 · How we verify

TJ101 injection Test Product

TJ Biopharma Co., Ltd. · Phase 1 active Small molecule ✓ Verified Jun 2026

TJ101 injection Test Product is a Small molecule drug developed by TJ Biopharma Co., Ltd.. It is currently in Phase 1 development.

TJ101 injection Test Product is being studied in a clinical trial involving healthy adult males in China to assess its bioequivalence to the TJ101 injection Reference Product following a change in its manufacturing process. The mechanism of action of TJ101 injection is currently unknown.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TJ101 injection Test Product
Sponsor	TJ Biopharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TJ101 injection Test Product CI brief — competitive landscape report
TJ101 injection Test Product updates RSS · CI watch RSS
TJ Biopharma Co., Ltd. portfolio CI

Frequently asked questions about TJ101 injection Test Product

What is TJ101 injection Test Product?

TJ101 injection Test Product is a Small molecule drug developed by TJ Biopharma Co., Ltd..

Who makes TJ101 injection Test Product?

TJ101 injection Test Product is developed by TJ Biopharma Co., Ltd. (see full TJ Biopharma Co., Ltd. pipeline at /company/tj-biopharma-co-ltd).

What development phase is TJ101 injection Test Product in?

TJ101 injection Test Product is in Phase 1.

Manufacturer: TJ Biopharma Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing